Why the study?
Does nisoldipine 40 mg once daily reduce the progression of coronary atherosclerosis or clinical events in patients who have undergone successful coronary angioplasty?
Population
826 patients who had undergone successful coronary angioplasty
Comparison
Nisoldipine 40 mg once daily vs Placebo
Design
RCT, randomised, double blind
Follow-up
3 years
Authors
Loading...
Nisoldipine reduces post-angioplasty clinical events via fewer revascularizations without angiographic benefit; challenges assumption that progression slowing drives clinical gains.
Does nisoldipine 40 mg once daily reduce the progression of coronary atherosclerosis or clinical events in patients who have undergone successful coronary angioplasty?
Nisoldipine does not prevent angiographic progression of coronary atherosclerosis or major cardiovascular events after successful angioplasty, but may reduce the need for subsequent revascularization.
J. Dens (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: